Literature DB >> 30920455

Pathogenesis and treatment of autoimmune rheumatic diseases.

Eric Liu1, Andras Perl.   

Abstract

PURPOSE OF REVIEW: Autoimmune diseases are of unknown origin, and they represent significant causes of morbidity and mortality. Here, we review new developments in the understanding of their pathogenesis that have led to development of well tolerated and effective treatments. RECENT
FINDINGS: In addition to the long-recognized genetic impact of the HLA locus, interferon regulatory factors, PTPN22, STAT4, and NOX have been implicated in pathogenesis of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Smoking, ultraviolet light, diet, and microbiota exert strong environmental influence on development of RA and SLE. Metabolism has been recognized as a critical integrator of genetic and environmental factors, and it controls immune cell differentiation both under physiological and pathological conditions.
SUMMARY: With the advent of high-throughput genetic, proteomic, and metabolomic technologies, the field of medicine has been shifting towards systems-based and personalized approaches to diagnose and treat common conditions, including rheumatic diseases. Regulatory checkpoints of metabolism and signal transduction, such as glucose utilization, mitochondrial electron transport, JAK, mTOR, and AMPK pathway activation, and production of pro-inflammatory cytokines IL-1, IL-6, and IL-17 have presented new targets for therapeutic intervention. This review amalgamates recent discoveries in genetics and metabolomics with immunological pathways of pathogenesis in rheumatic diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30920455      PMCID: PMC6447054          DOI: 10.1097/BOR.0000000000000594

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  123 in total

1.  Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.

Authors:  Shuling Zhang; Julie A Readinger; Wendy DuBois; Mirkka Janka-Junttila; Richard Robinson; Margaret Pruitt; Val Bliskovsky; Julie Z Wu; Kaori Sakakibara; Jyoti Patel; Carole A Parent; Lino Tessarollo; Pamela L Schwartzberg; Beverly A Mock
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

2.  Integration of genetics and miRNA-target gene network identified disease biology implicated in tissue specificity.

Authors:  Saori Sakaue; Jun Hirata; Yuichi Maeda; Eiryo Kawakami; Takuro Nii; Toshihiro Kishikawa; Kazuyoshi Ishigaki; Chikashi Terao; Ken Suzuki; Masato Akiyama; Naomasa Suita; Tatsuo Masuda; Kotaro Ogawa; Kenichi Yamamoto; Yukihiko Saeki; Masato Matsushita; Maiko Yoshimura; Hidetoshi Matsuoka; Katsunori Ikari; Atsuo Taniguchi; Hisashi Yamanaka; Hideya Kawaji; Timo Lassmann; Masayoshi Itoh; Hiroyuki Yoshitomi; Hiromu Ito; Koichiro Ohmura; Alistair R R Forrest; Yoshihide Hayashizaki; Piero Carninci; Atsushi Kumanogoh; Yoichiro Kamatani; Michiel de Hoon; Kazuhiko Yamamoto; Yukinori Okada
Journal:  Nucleic Acids Res       Date:  2018-12-14       Impact factor: 16.971

3.  The activation status of human macrophages presenting antigen determines the efficiency of Th17 responses.

Authors:  Christina E Arnold; Peter Gordon; Robert N Barker; Heather M Wilson
Journal:  Immunobiology       Date:  2015-01       Impact factor: 3.144

Review 4.  Role of viruses and bacteria-virus interactions in autoimmunity.

Authors:  Ashley L Steed; Thaddeus S Stappenbeck
Journal:  Curr Opin Immunol       Date:  2014-10-27       Impact factor: 7.486

5.  Early-stage lupus nephritis treated with N-acetylcysteine: A report of two cases.

Authors:  Ming Li; Wenjuan Gao; Jingjing Ma; Yun Zhu; Xingfu Li
Journal:  Exp Ther Med       Date:  2015-05-21       Impact factor: 2.447

6.  Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.

Authors:  R G Langley; M Lebwohl; G G Krueger; P O Szapary; Y Wasfi; D Chan; M C Hsu; Y You; Y Poulin; N Korman; J C Prinz; K Reich
Journal:  Br J Dermatol       Date:  2015-03-22       Impact factor: 9.302

7.  Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis.

Authors:  Bernard Vandooren; Troy Noordenbos; Carmen Ambarus; Sarah Krausz; Tineke Cantaert; Nataliya Yeremenko; Maartje Boumans; Rene Lutter; Paul P Tak; Dominique Baeten
Journal:  Arthritis Rheum       Date:  2009-04

8.  Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus.

Authors:  David Fernandez; Eduardo Bonilla; Naureen Mirza; Brian Niland; Andras Perl
Journal:  Arthritis Rheum       Date:  2006-09

9.  Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus.

Authors:  Zhi-Wei Lai; Rebecca Borsuk; Ashwini Shadakshari; Jianghong Yu; Maha Dawood; Ricardo Garcia; Lisa Francis; Hajra Tily; Adam Bartos; Stephen V Faraone; Paul Phillips; Andras Perl
Journal:  J Immunol       Date:  2013-08-02       Impact factor: 5.422

Review 10.  Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway.

Authors:  Ana Catarina Lunz Macedo; Lourdes Isaac
Journal:  Front Immunol       Date:  2016-02-24       Impact factor: 7.561

View more
  7 in total

Review 1.  Metabolic determinants of lupus pathogenesis.

Authors:  Xiangyu Teng; Josephine Brown; Seung-Chul Choi; Wei Li; Laurence Morel
Journal:  Immunol Rev       Date:  2020-03-12       Impact factor: 12.988

Review 2.  Neutrophils in the Pathogenesis of Rheumatic Diseases: Fueling the Fire.

Authors:  Yudong Liu; Mariana J Kaplan
Journal:  Clin Rev Allergy Immunol       Date:  2020-11-05       Impact factor: 8.667

Review 3.  The NADase enzyme CD38: an emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Thais Ribeiro Peclat; Bo Shi; John Varga; Eduardo Nunes Chini
Journal:  Curr Opin Rheumatol       Date:  2020-11       Impact factor: 4.941

4.  Experience of therapeutic plasma exchange in rheumatic diseases: Albumin may be a suitable substitute for plasma.

Authors:  Zhiqian Bai; Yu Chen; Lingli Dong
Journal:  Arch Rheumatol       Date:  2021-03-16       Impact factor: 1.472

5.  Relationship between amniotic fluid metabolic profile with fetal gender, maternal age, and gestational week.

Authors:  Yahong Li; Yun Sun; Xiaojuan Zhang; Xin Wang; Peiying Yang; Xianwei Guan; Yan Wang; Xiaoyan Zhou; Ping Hu; Tao Jiang; Zhengfeng Xu
Journal:  BMC Pregnancy Childbirth       Date:  2021-09-18       Impact factor: 3.007

Review 6.  A Systematic Review of Nutritional Interventions on Key Cytokine Pathways in Rheumatoid Arthritis and Its Implications for Comorbid Depression: Is a More Comprehensive Approach Required?

Authors:  Michelle Lanspa; Breanne Kothe; Myla R Pereira; Marc M Kesselman; Stephanie N Petrosky
Journal:  Cureus       Date:  2022-08-15

Review 7.  Metabolomics in Autoimmune Diseases: Focus on Rheumatoid Arthritis, Systemic Lupus Erythematous, and Multiple Sclerosis.

Authors:  Naeun Yoon; Ah-Kyung Jang; Yerim Seo; Byung Hwa Jung
Journal:  Metabolites       Date:  2021-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.